Capmatinib vs Tepotinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: MET · full Non-Small Cell Lung Cancer pipeline

Capmatinib

Marketed by Novartis and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT04427072 · Phase 3 · terminated

This randomized, open-label trial compared capmatinib to docetaxel in patients with MET exon 14-mutant lung cancer, but enrolled only 22 participants (15 on capmatinib, 7 on docetaxel) before the sponsor terminated the study early. Median progression-free survival was numerically longer with capmatinib (6.1 vs 4.1 months), but the confidence intervals were wide and overlapping and no formal statistical test was reported, so this severely underpowered trial cannot reliably show whether capmatinib truly outperformed docetaxel.

Next expected readout: April 2027 · NCT05488314 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months (unclear)

Result source: NCT04427072

Tepotinib · Tepmetko

Marketed by Merck KGaA and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT02864992 · Phase 2 · active, not recruiting

The study was open-label and had no randomized comparator arm, so the reported tumor responses cannot be distinguished from outcomes that might have occurred with other treatment or without tepotinib. Although response was assessed by an independent review committee and results were reported for 337 participants, the primary endpoint was descriptive in this single-arm design.

Next expected readout: December 2027 · NCT06083857 (registry estimate)

Reported efficacy

Objective response rate (ORR) by independent review committee (IRC): ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months (not_applicable)

Result source: NCT02864992

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCapmatinibTepotinib
PFS, median6.1 vs 4.1vs Docetaxeln 15NCT04427072
4 other results
4.9 vs 4.4vs Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg · n 31NCT01982955
1 other result
  • 10.2 vs 4.3 500 mg + 250 mg · n 31 · Phase 1/2 · secondary NCT01982955
OS, median12.5 vs 13.6vs Docetaxeln 15NCT04427072
17 other results
17.3 vs 19.5vs Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg · n 31NCT01982955
ORR53.3% vs 0%vs Docetaxeln 15NCT04427072
30 other results
45.2% vs 33.3%vs Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg · n 31NCT01982955
2 other results
  • 33.3% 500 mg + 250 mg · n 12 · Phase 1/2 · secondary NCT01982955
  • 33.3% 300 mg + 250 mg · n 6 · Phase 1/2 · secondary NCT01982955
Duration of response, median9.9 vs 3.1vs Docetaxeln 7NCT04427072
34 other results
—Trial running · NCT06908993

PFS, median

Capmatinib
6.1 vs 4.1vs Docetaxeln 15NCT04427072
4 other results
Tepotinib
4.9 vs 4.4vs Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg · n 31NCT01982955
1 other result
  • 10.2 vs 4.3 500 mg + 250 mg · n 31 · Phase 1/2 · secondary NCT01982955

OS, median

Capmatinib
12.5 vs 13.6vs Docetaxeln 15NCT04427072
17 other results
Tepotinib
17.3 vs 19.5vs Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg · n 31NCT01982955

ORR

Capmatinib
53.3% vs 0%vs Docetaxeln 15NCT04427072
30 other results
Tepotinib
45.2% vs 33.3%vs Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg · n 31NCT01982955
2 other results
  • 33.3% 500 mg + 250 mg · n 12 · Phase 1/2 · secondary NCT01982955
  • 33.3% 300 mg + 250 mg · n 6 · Phase 1/2 · secondary NCT01982955

Duration of response, median

Capmatinib
9.9 vs 3.1vs Docetaxeln 7NCT04427072
34 other results
Tepotinib
—Trial running · NCT06908993
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. Capmatinib: 7 of 7 rows · Tepotinib: 6 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCapmatinib
Rows use multiple source trials
Tepotinib
Disease Control
responder rate · % of participants
73.3% (n=15) vs 57.1% (n=7) Docetaxela,b,c,d,e
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
show 1 more dose
86.7% (n=15) vs 42.9% (n=7) Docetaxel
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
83.9% (n=31) vs 70.8% (n=24) Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mgb,c,d,e
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Disease Control
responder rate · % of participants
No placebo or comparator arm
80% (n=20) @ 12wkf,c,g,e
NCT02750215 · Phase 2 · registry result, not featured evidence
58.3% (n=12)500 mg + 250 mga,f,c,g,e
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more dose
50% (n=6)300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
ORR
responder rate · % of participants
No placebo or comparator arm
29% (n=69)a,f,h,e
NCT02414139 · Phase 2
show 23 more doses
27.5% (n=69)
NCT02414139 · Phase 2
11.9% (n=42)
NCT02414139 · Phase 2
7.1% (n=42)
NCT02414139 · Phase 2
9.3% (n=54)
NCT02414139 · Phase 2
9.3% (n=54)
NCT02414139 · Phase 2
6.7% (n=30)
NCT02414139 · Phase 2
3.3% (n=30)
NCT02414139 · Phase 2
44% (n=100)
NCT02414139 · Phase 2 · combination
44% (n=100)
NCT02414139 · Phase 2 · combination
40.6% (n=69)
NCT02414139 · Phase 2
43.5% (n=69)
NCT02414139 · Phase 2
40% (n=15)
NCT02414139 · Phase 2
40% (n=15)
NCT02414139 · Phase 2
68.3% (n=60)
NCT02414139 · Phase 2 · combination
58.3% (n=60)
NCT02414139 · Phase 2 · combination
67.9% (n=28)
NCT02414139 · Phase 2
60.7% (n=28)
NCT02414139 · Phase 2
0% (n=3)
NCT02414139 · Phase 2
0% (n=3)
NCT02414139 · Phase 2
51.6% (n=31)
NCT02414139 · Phase 2
45.2% (n=31)
NCT02414139 · Phase 2
68.8% (n=32)
NCT02414139 · Phase 2
56.3% (n=32)
NCT02414139 · Phase 2
33.3% (n=12)500 mg + 250 mga,f,h,e
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more dose
33.3% (n=6)300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Dropout rate
n/a: no completion milestoneCapmatinibi
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
show 37 more results
—Capmatinib (On-treatment)
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
—Capmatinib Extension Crossover Tre
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
n/a: no completion milestoneCohort 1a: Pre-treated Patients Wi
NCT02414139 · Phase 2
n/a: no completion milestoneCohort 1b: Pre-treated Patients Wi
NCT02414139 · Phase 2
n/a: no completion milestoneCohort 2: Pre-treated Patients Wit
NCT02414139 · Phase 2
n/a: no completion milestoneCohort 3: Pre-treated Patients Wit
NCT02414139 · Phase 2
n/a: no completion milestoneCohort 4: Pre-treated Patients Wit
NCT02414139 · Phase 2
n/a: no completion milestoneCohort 5a: Treatment-naïve Patient
NCT02414139 · Phase 2
n/a: no completion milestoneCohort 5b: Treatment-naïve Patient
NCT02414139 · Phase 2
n/a: no completion milestoneCohort 6.1 (Expansion of Cohort 1a
NCT02414139 · Phase 2
n/a: no completion milestoneCohort 6.2 (Expansion of Cohort 4)
NCT02414139 · Phase 2
n/a: no completion milestoneCohort 7 (Expansion of Cohort 5b):
NCT02414139 · Phase 2
86.7%Cohort 1
NCT04677595 · Phase 2 · registry result, not featured evidence
90.5%Cohort 2
NCT04677595 · Phase 2 · registry result, not featured evidence
0%
NCT02750215 · Phase 2 · registry result, not featured evidence
—800 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone800 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—600 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone600 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone400 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone200 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone200 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone200 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—100 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
0%500 mg + 250 mgj
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
0%500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
0%300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
20%Capmatinibi
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
show 37 more results
—Capmatinib (On-treatment)
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
—Capmatinib Extension Crossover Tre
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
15.9%Cohort 1a: Pre-treated Patients Wi
NCT02414139 · Phase 2
14.3%Cohort 1b: Pre-treated Patients Wi
NCT02414139 · Phase 2
14.8%Cohort 2: Pre-treated Patients Wit
NCT02414139 · Phase 2
16.7%Cohort 3: Pre-treated Patients Wit
NCT02414139 · Phase 2
20.3%Cohort 4: Pre-treated Patients Wit
NCT02414139 · Phase 2
20%Cohort 5a: Treatment-naïve Patient
NCT02414139 · Phase 2
21.4%Cohort 5b: Treatment-naïve Patient
NCT02414139 · Phase 2
33.3%Cohort 6.1 (Expansion of Cohort 1a
NCT02414139 · Phase 2
19.4%Cohort 6.2 (Expansion of Cohort 4)
NCT02414139 · Phase 2
25%Cohort 7 (Expansion of Cohort 5b):
NCT02414139 · Phase 2
13.3%Cohort 1
NCT04677595 · Phase 2 · registry result, not featured evidence
28.6%Cohort 2
NCT04677595 · Phase 2 · registry result, not featured evidence
—
NCT02750215 · Phase 2 · registry result, not featured evidence
—800 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
14.3%800 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—600 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
0%600 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
15.1%400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
8.3%400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
0%400 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
12.8%400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
25%400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
25%200 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
0%200 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
0%200 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—100 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
0%100 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—500 mg + 250 mgj
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
—500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
—Capmatinibi
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
show 37 more results
20%Capmatinib (On-treatment)
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
20%Capmatinib Extension Crossover Tre
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
—Cohort 1a: Pre-treated Patients Wi
NCT02414139 · Phase 2
—Cohort 1b: Pre-treated Patients Wi
NCT02414139 · Phase 2
—Cohort 2: Pre-treated Patients Wit
NCT02414139 · Phase 2
—Cohort 3: Pre-treated Patients Wit
NCT02414139 · Phase 2
—Cohort 4: Pre-treated Patients Wit
NCT02414139 · Phase 2
—Cohort 5a: Treatment-naïve Patient
NCT02414139 · Phase 2
—Cohort 5b: Treatment-naïve Patient
NCT02414139 · Phase 2
—Cohort 6.1 (Expansion of Cohort 1a
NCT02414139 · Phase 2
—Cohort 6.2 (Expansion of Cohort 4)
NCT02414139 · Phase 2
—Cohort 7 (Expansion of Cohort 5b):
NCT02414139 · Phase 2
46.7%Cohort 1
NCT04677595 · Phase 2 · registry result, not featured evidence
66.7%Cohort 2
NCT04677595 · Phase 2 · registry result, not featured evidence
10%
NCT02750215 · Phase 2 · registry result, not featured evidence
42.9%800 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—800 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
60%600 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—600 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
22.6%400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
33.3%400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
33.3%400 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
40.4%400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
37.5%400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
0%200 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
28.6%200 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
71.4%200 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Cap BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—200 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
20%100 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
—100 mg Cap QD
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
58.3%500 mg + 250 mgj
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
41.9%500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
66.7%300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
i
oedema peripheral 66.7%
vomiting 40%
cough 33.3%
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
show 15 more results
alopecia 80%
anaemia 60%
asthenia 40%
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
hypoalbuminaemia 60%
hypocalcaemia 53.3%
alanine aminotransferase increased 33.3%
NCT04677595 · Phase 2 · registry result, not featured evidence
hypocalcaemia 52.4%
oedema peripheral 47.6%
hypoalbuminaemia 42.9%
NCT04677595 · Phase 2 · registry result, not featured evidence
edema limbs 65%
fatigue 35%
nausea 35%
NCT02750215 · Phase 2 · registry result, not featured evidence
800 mg Cap QD
vomiting 100%
nausea 85.7%
decreased appetite 57.1%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
600 mg Cap BID
cough 60%
decreased appetite 60%
hypoproteinaemia 40%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
400 mg Cap BID
hypoalbuminaemia 43.4%
anaemia 34%
oedema peripheral 28.3%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
400 mg Cap BID
hypoalbuminaemia 58.3%
blood bilirubin increased 41.7%
amylase increased 33.3%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
400 mg Cap QD
nausea 50%
cough 33.3%
oedema peripheral 33.3%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
400 mg Tab BID
nausea 55.3%
oedema peripheral 44.7%
decreased appetite 40.4%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
400 mg Tab BID
decreased appetite 37.5%
diarrhoea 37.5%
headache 37.5%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
200 mg Cap BID
diarrhoea 75%
hypoalbuminaemia 75%
anaemia 50%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
200 mg Cap QD
back pain 57.1%
rash 42.9%
vomiting 42.9%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
200 mg Tab BID
nausea 71.4%
dermatitis acneiform 57.1%
cystitis 42.9%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
100 mg Cap QD
constipation 60%
pruritus 60%
amylase increased 40%
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
500 mg + 250 mgj
diarrhoea 83.3%
dyspnoea exertional 41.7%
fatigue 41.7%
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
500 mg + 250 mg
diarrhoea 58.1%
oedema peripheral 38.7%
amylase increased 35.5%
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
300 mg + 250 mg
amylase increased 66.7%
diarrhoea 66.7%
blood alkaline phosphatase increased 50%
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 3 versus Phase 1/2.
  3. cPopulation context differs: registered conditions differ.
  4. dTreatment context differs: monotherapy versus combination.
  5. eThe assessment timepoint is not available for both results.
  6. fTrial phases differ: Phase 2 versus Phase 1/2.
  7. gTreatment context has not been resolved for both arms.
  8. hPopulation comparability has not been reviewed for both studies.
  9. iPopulation comparability has not been reviewed for 35 of these studies.
  10. jPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Capmatinib

Time to Response 3.2 months
time to event · months
No placebo or comparator arm
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
show 22 more results
1.4 months
NCT02414139 · Phase 2
2.8 months
NCT02414139 · Phase 2
1.4 months
NCT02414139 · Phase 2
3.4 months
NCT02414139 · Phase 2
1.4 months
NCT02414139 · Phase 2
1.4 months
NCT02414139 · Phase 2
1.4 months
NCT02414139 · Phase 2
1.4 months
NCT02414139 · Phase 2
1.4 months
NCT02414139 · Phase 2
1.4 months
NCT02414139 · Phase 2 · combination
1.4 months
NCT02414139 · Phase 2 · combination
1.4 months
NCT02414139 · Phase 2
1.4 months
NCT02414139 · Phase 2
1.3 months
NCT02414139 · Phase 2
1.3 months
NCT02414139 · Phase 2
1.4 months
NCT02414139 · Phase 2
1.4 months
NCT02414139 · Phase 2
1.4 months
NCT02414139 · Phase 2
1.4 months
NCT02414139 · Phase 2
1.4 months
NCT02414139 · Phase 2
1.4 months
NCT02414139 · Phase 2 · combination
1.4 months
NCT02414139 · Phase 2 · combination
Time to Response 1.3 vs 2.8 Docetaxel months
time to event · months
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
Duration of Response 5.6 months400 mg Cap BID
time to event · months
No placebo or comparator arm
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
show 37 more results
5.6 months400 mg Tab BID
NCT01610336 · Phase 2 · registry result, not featured evidence · combination
12.6 months
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
8.31 months
NCT02414139 · Phase 2
24.94 months
NCT02414139 · Phase 2
9.66 months
NCT02414139 · Phase 2
4.19 months
NCT02414139 · Phase 2
9.72 months
NCT02414139 · Phase 2
7.54 months
NCT02414139 · Phase 2
12.58 months
NCT02414139 · Phase 2
9.05 months
NCT02414139 · Phase 2
16.59 months
NCT02414139 · Phase 2
9.72 months
NCT02414139 · Phase 2 · combination
16.59 months
NCT02414139 · Phase 2 · combination
6.8 months
NCT02414139 · Phase 2
6.93 months
NCT02414139 · Phase 2
19.48 months
NCT02414139 · Phase 2
6.93 months
NCT02414139 · Phase 2
8.31 months
NCT02414139 · Phase 2
9.66 months
NCT02414139 · Phase 2
13.83 months
NCT02414139 · Phase 2
14.57 months
NCT02414139 · Phase 2
15.21 months
NCT02414139 · Phase 2
8.38 months
NCT02414139 · Phase 2 · combination
13.96 months
NCT02414139 · Phase 2 · combination
8.46 months
NCT04677595 · Phase 2 · registry result, not featured evidence
NA months
NCT04677595 · Phase 2 · registry result, not featured evidence
7.08 months
NCT04677595 · Phase 2 · registry result, not featured evidence
15.8 months
NCT04677595 · Phase 2 · registry result, not featured evidence
9.79 months
NCT04677595 · Phase 2 · registry result, not featured evidence
NA months
NCT04677595 · Phase 2 · registry result, not featured evidence
NA months
NCT04677595 · Phase 2 · registry result, not featured evidence
NA months
NCT04677595 · Phase 2 · registry result, not featured evidence
11.17 months
NCT04677595 · Phase 2 · registry result, not featured evidence
4.17 months
NCT04677595 · Phase 2 · registry result, not featured evidence
6.41 months
NCT04677595 · Phase 2 · registry result, not featured evidence
19.61 months
NCT04677595 · Phase 2 · registry result, not featured evidence
3.8 months
NCT02750215 · Phase 2 · registry result, not featured evidence
Duration of Response 9.9 vs 3.1 Docetaxel months
time to event · months
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
Intracranial 0% (n=1)
responder rate · % of participants
No placebo or comparator arm
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
show 1 more result
0% (n=4) @ 12wk
NCT02750215 · Phase 2 · registry result, not featured evidence
Intracranial Disease Control 100% (n=1)
responder rate · % of participants
No placebo or comparator arm
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
show 2 more results
100% (n=4)
NCT04677595 · Phase 2 · registry result, not featured evidence
100% (n=3)
NCT04677595 · Phase 2 · registry result, not featured evidence
EORTC QLQ-C30 Global Health Status 17.4 vs 4.2 Docetaxel score @ 6wk
absolute change · score
Global Health Status CFB at Cycle 3, Day 1 n=12,4
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
EORTC QLQ-C30 Global Health Status 14.6 vs 8.3 Docetaxel score @ 12wk
absolute change · score
Global Health Status CFB at Cycle 5, Day 1 n=8,3
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
EORTC QLQ-C30 Global Health Status 15.6 vs -8.3 Docetaxel score @ 18wk
absolute change · score
Global Health Status CFB at Cycle 7, Day 1 n=8,1
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
EORTC QLQ-C30 Global Health Status 9.5 vs 0 Docetaxel score @ 24wk
absolute change · score
Global Health Status CFB at Cycle 9, Day 1 n=7,2
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
EORTC QLQ-C30 Global Health Status 3.6 score @ 30wk
absolute change · score
No placebo or comparator arm
Global Health Status CFB at Cycle 11, Day 1 n=7,0
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3
EORTC QLQ-C30 Global Health Status 25 score @ 36wk
absolute change · score
No placebo or comparator arm
Global Health Status CFB at Cycle 13, Day 1 n=5,0
NCT04427072 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer with MET Exon 14 Skipping · phase 3

+ 390 further endpoints in the CSV export.

Tepotinib

EORTC QLQ-C30 GHS -16.29 vs -2.78 Pemetrexed and Cisplatin/Carboplatin score500 mg + 250 mg
absolute change · score
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Time to Symptomatic Progression 5.75 vs 7.95 Pemetrexed and Cisplatin/Carboplatin months500 mg + 250 mg
time to event · months
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Capmatinib's landscape · Tepotinib's landscape